Simplifying Global Compliance
Wingspan Stent’s Benefits Don’t Justify Risks, Panel Concludes
Devices & Diagnostics Letter
Stryker’s Wingspan stent could be yanked from the market if the FDA heeds March 23 recommendations of its Neurological Devices Panel.
To View This Article:
Buy This Article Now
Copyright ©2017. All Rights Reserved.
Design, CMS, Hosting & Web Development :: ePublishing